Why Your Notified Body Timeline Just Collapsed

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This scenario plays out constantly across the medical device industry. Manufacturers plan their submissions around published timelines. They allocate resources. They commit to commercial partners. Then the process extends, stalls, or restarts entirely.

The issue is not just delay. The issue is that most manufacturers misunderstand how Notified Body timelines actually work under MDR. They treat the process as linear when it is fundamentally conditional.

The Clock You Think Is Running

When you look at MDR Article 52, you see defined timeframes. The regulation states that the Notified Body shall endeavor to complete the conformity assessment within certain periods depending on device class and novelty.

For Class III devices, this can be up to 90 days for standard products or longer for high-risk or innovative devices. For Class IIb and IIa, the timelines are shorter in principle.

But here is what actually determines your timeline: the completeness of your submission and the quality of your clinical evaluation.

The clock starts when the Notified Body receives what it considers a complete and adequate dossier. Not when you submit. When they consider it complete.

Most delays happen in this invisible phase. You think you are waiting for feedback. The Notified Body thinks you submitted an incomplete file.

What Completeness Actually Means

Completeness is not just about having all documents present. It means having documents that can be reviewed without constant clarification.

Your Clinical Evaluation Report is the primary gatekeeper. If the assessor opens your CER and finds incomplete SOTA, weak equivalence claims, or missing appraisal of clinical data, the clock does not start.

They will send you a preliminary list of observations. You respond. They review your response. If it is inadequate, they send another round. This can go on for weeks before the formal assessment even begins.

I have seen files cycle through three rounds of preliminary questions before the Notified Body officially accepted the submission. Each round took two to three weeks. That is two months gone before day one of the official timeline.

Why does this happen? Because manufacturers treat the CER as a compliance document instead of an evidence file. They focus on structure and forget that the assessor needs to understand your clinical rationale without asking for clarification.

What Triggers Pre-Assessment Delays

The most common triggers are predictable:

Incomplete literature searches. The assessor cannot validate your SOTA if they do not understand your search strategy. If your inclusion criteria are vague or your search terms are too narrow, they will ask for a revised search.

Equivalence claims without proper demonstration. You claim equivalence to a predicate device but do not fully justify technical and biological equivalence. The assessor cannot accept the claim without that demonstration. You now need to provide additional testing or revise your clinical strategy entirely.

Clinical data with unresolved gaps. Your device has known complications in the literature. You acknowledge them but do not adequately address how your device mitigates those risks. The assessor will not proceed until you close that gap.

PMCF plan that lacks specificity. You state you will conduct post-market surveillance but do not define methods, endpoints, or timelines. The Notified Body cannot approve a device with an incomplete post-market strategy.

The Clock Stops More Than You Think

Even after the official timeline starts, it does not run continuously. MDR Article 52 allows the Notified Body to stop the clock when they request additional information.

This is where manufacturers lose control of their schedule. Every question from the Notified Body pauses the timeline until you respond. The regulation does not limit how long you can take to respond, but in practice, Notified Bodies expect turnaround within 20 to 30 days.

If your response is incomplete or introduces new issues, the clock does not restart immediately. The assessor must review your response. If they need further clarification, the clock stays paused.

Here is the trap: each round of questions reveals how well you understood the previous round. If you answer narrowly—addressing only what was asked without anticipating the underlying concern—you create another cycle.

I have reviewed responses where the manufacturer answered the literal question but missed the clinical reasoning behind it. The Notified Body asked about a specific complication rate. The manufacturer provided data but did not explain how their device design mitigates that risk. The assessor asked again, now more specifically. Another two weeks gone.

How Questions Multiply

Questions do not exist in isolation. When the Notified Body identifies a gap in one section, they often find related gaps elsewhere.

If your SOTA is weak on long-term outcomes, they will also question your PMCF plan. If your equivalence claim lacks biomechanical testing, they will also scrutinize your risk analysis for mechanical failure modes.

This is not the Notified Body being difficult. This is them doing their job. Under MDR, they must ensure your clinical evaluation is thorough and your risk-benefit profile is clearly favorable. If one part of your clinical rationale is weak, it raises doubts about the rest.

Manufacturers who do not anticipate this interconnection face exponential delays. One question becomes three. Three questions reveal a systemic issue in how clinical evidence was compiled. Now you are not just answering questions. You are revising your CER.

Commercial Pressure Versus Regulatory Reality

The tension is always the same. Your commercial team planned a launch based on the published timeline. Your regulatory team knows the timeline is conditional. Your clinical evaluation team is trying to close gaps that should have been addressed months ago.

When the delay happens, everyone looks for someone to blame. The Notified Body is slow. The regulation is unreasonable. The clinical evaluation was rushed.

But the root cause is almost always the same: the clinical evaluation was not ready for scrutiny.

Under the old directives, you could get through with a thinner file. The Notified Body asked fewer questions. The bar was lower. MDR changed this fundamentally. Now, the clinical evaluation is the core of your submission. If it is weak, everything else collapses.

I work with manufacturers who understand this. They invest time upfront in their CER. They conduct proper literature reviews. They justify their equivalence claims rigorously. They design PMCF plans that actually generate useful data.

When they submit, the Notified Body has fewer questions. The review process is faster. The timeline holds.

What Upfront Rigor Looks Like

It means completing your SOTA before you finalize your device design. It means testing your equivalence claim with real comparative data, not assumptions. It means drafting your PMCF plan as if you will actually execute it, because you will.

It also means internal review before submission. Have someone outside your project team read your CER critically. Do they understand your clinical rationale? Can they follow your literature appraisal? Are your conclusions supported by the evidence you presented?

If your internal reviewer has questions, the Notified Body will too. Better to find those gaps before submission than during the assessment.

Building Margin Into Your Planning

Even with a strong submission, you should plan for questions. No file is perfect. No clinical evaluation anticipates every assessor concern.

A realistic timeline includes margin for at least one round of clarification. For higher-risk devices or novel technologies, plan for two rounds.

Each round adds four to six weeks: two weeks for the Notified Body to formulate questions, two to three weeks for you to respond, another week or two for them to review your response.

If your commercial launch depends on hitting the minimum published timeline, you have no margin for anything unexpected. And in medical device regulation, something unexpected always happens.

Communication With Your Notified Body

Timelines also depend on how you communicate. When you receive questions, respond completely. Do not answer in pieces. Do not assume you can clarify later.

If a question is unclear, ask for clarification before you respond. A wrong answer costs more time than a request for clarification.

If you need more time to respond properly, inform the Notified Body in advance. Do not let deadlines pass silently. Silence signals disorganization, which raises concerns about your quality system.

Throughout the process, keep your Notified Body informed of any major changes to your device, your clinical data, or your intended use. Surprises during review create delays. Transparency creates trust.

The Real Timeline Equation

Your actual timeline is not the published timeline. It is:

Pre-assessment phase (completeness check, preliminary questions) + Formal assessment phase (official review clock) + Clarification rounds (questions, responses, re-reviews) + Final decision phase (certificate issuance).

The only part you control is the quality of your submission. A strong clinical evaluation reduces pre-assessment cycles. Clear documentation reduces clarification rounds. Responsive communication reduces review delays.

Manufacturers who understand this equation do not try to beat the timeline. They try to eliminate the variables that extend it.

The result is not always speed. But it is predictability. And in regulatory affairs, predictability is more valuable than speed.

When your clinical evaluation is solid, when your technical documentation is complete, when your responses are thorough, the Notified Body has no reason to delay. They move through their process efficiently because you gave them everything they need to assess your device.

That is timeline management under MDR. Not negotiation. Not pressure. Just readiness.

Where to Focus Your Effort

If you want to control your timeline, focus on three areas:

First, your clinical evaluation. Make it thorough. Make it clear. Make it defensible. Everything else depends on this foundation.

Second, your pre-submission preparation. Review your own file critically before submission. Identify gaps. Close them. Do not rely on the Notified Body to tell you what is missing.

Third, your response quality. When questions come, answer them completely. Address the underlying concern, not just the literal question. One thorough response is faster than three partial responses.

These three areas determine whether your timeline holds or collapses. Work on them before submission, not during review.

The regulation gives Notified Bodies the authority to stop the clock whenever they need more information. You cannot change that. But you can control how often they need to stop it.

That is where your leverage is. That is where your timeline lives.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.